Updates from the CAPTIVATE Study Evaluating Ibrutinib + Venetoclax in TN CLL/SLL

Opinion
Video

An expert on hematologic malignancies discusses the ongoing CAPTIVATE trial evaluating ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL.

Video content above is prompted by the following questions:

  • Please briefly discuss the ongoing CAPITIVATE trial, evaluating ibrutinib plus venetoclax for the treatment of treatment naïve CLL/SLL.
    • Please discuss the latest data from the CAPTIVATE trial.
      • What are the key takeaways from the results of this study?
      • How do the outcomes impact patients with high-risk genomic features?
Recent Videos
1 KOL is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Related Content
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL

Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL

Targeted Oncology Staff
December 18th 2024
Article

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Pirtobrutinib Combination Shows High uMRD Rate in CLL

Pirtobrutinib Combination Shows High uMRD Rate in CLL

Ariana Pelosci
December 12th 2024
Article

Pirtobrutinib, venetoclax, and obinutuzumab demonstrated a numerically higher rate of undetectable minimal residual disease vs ibrutinib and venetoclax in chronic lymphocytic leukemia.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Pirtobrutinib Boosts PFS and Sustains BTK Inhibition in Patients With CLL/SLL

Pirtobrutinib Boosts PFS and Sustains BTK Inhibition in Patients With CLL/SLL

Tony Berberabe, MPH
December 10th 2024
Article

Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment discontinuation rates vs investigator's choice in previously treated CLL/SLL.

Read More

Sonrotoclax and Zanubrutinib Shows Strong Efficacy in Untreated CLL/SLL

Sonrotoclax and Zanubrutinib Shows Strong Efficacy in Untreated CLL/SLL

Silas Inman
December 10th 2024
Article

Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.

Read More